Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Organicell Regenerative Medicine Inc BPSR


Primary Symbol: OCEL

Healthcare Biotechnology
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of biological therapeutics for the treatment of degenerative diseases and to provide other related services. RAAM products are used in the healthcare industry administered through doctors and clinics. Its leading product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. The product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes derived from perinatal tissues. It has obtained certain Investigation New Drug (IND), and emergency IND (eIND) approvals from the United States Food and Drug Administration (FDA), including applicable Institutional Review Board (IRB) approvals which authorized the Company to commence clinical trials.


OTCQB:OCEL - Post by User

Organicell Regenerative Medicine Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by indaknownewfieon Jun 16, 2021 1:30pm
141 Views
Post# 33395928

Ramping up

Ramping upUS based results from Houston out. News from India and Pakistan in a couple of weeks. 

https://www.pharmaceutical-technology.com/uncategorised/coronavirus-company-news-summary-organicell-regenerative-medicine-announces-positive-results-from-covid-19-drug-trial-moderna-and-magenta-investments-partner-to-distribute-covid-19-vaccine/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities